NB001

NB001 is a fully humanized and proprietary mAb that exhibits exceptional selectivity and affinity for B7H3. In MMAE ADC modality, the antibody exerts robust potency in picomolar range.

B7H3, also known as CD276, is a cell surface glycoprotein categorized within the B7 family of immune checkpoint molecules. Elevated levels of B7H3 expression have been correlated with unfavorable clinical outcomes. Targeting B7H3 through monoclonal antibodies (mAbs), ADCs, and CAR T-cell therapies has demonstrated efficacy in preclinical models and is currently in clinical trials. Combining B7H3-targeted therapies with other modalities like immune checkpoint blockers (ICBs), chemotherapy, or neo-adjuvant therapy shows promise as a novel treatment approach in multiple tumor types.

The NB001 antibody, fully humanized and proprietary, exhibits a remarkable level of selectivity and demonstrates affinity within the single-digit or low two-digit nanomolar (nM) range. This antibody can be effectively employed in various therapeutic modalities (Ex: ADC, CAR T cell therapy). As MMAE-ADC, with a drug-to-antibody ratio (DAR) greater than 8, NB001 has successfully passed rigorous biophysical quality control (QC) assessments. In this format, NB001 exhibits picomolar (pM) potency in tumor cell lines expressing B7H3. Neologics Bioscience aims to advance its NB001 assets through collaborative partnerships and out-licensing.

Click to expand